Absorbable Putty for Bone Hemostasis and Osteogenesis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current bone hemostasis and healing techniques face challenges with non-absorbable bone waxes, electrocautery, and existing absorbable materials that fail to effectively control osseous hemorrhage and promote bone healing due to issues with cohesiveness, biocompatibility, and absorption rates.

Innovation Solution

Development of absorbable putty-like compositions with varying viscosities and cohesive strengths, incorporating finely powdered bulking agents and dispersing vehicles, which provide immediate hemostasis, promote bone healing, and include additives like growth factors, anti-infectives, and radiopaque substances for enhanced osteogenesis and infection control.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If non-absorbable bone waxes are used for hemostasis, then immediate hemostatic effect is achieved, but osteogenesis is inhibited and permanent foreign body remains

Engineering Contradiction:
Improvehemostatic effectVSAvoidabsorption time
Core Design Contradiction:
ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent changes the physical and chemical parameters of bone wax by incorporating absorbable polymers (polyglycolide, polylactide, copolymers) to replace or supplement non-absorbable components. This allows the material to maintain hemostatic effectiveness while being gradually absorbed by the body, transforming it from a permanent foreign body to a temporary hemostatic agent that facilitates osteogenesis.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention creates composite materials combining absorbable polymers with traditional bone wax components or other hemostatic agents. These composites provide both immediate hemostatic effect and subsequent absorption capability, resolving the contradiction between effective hemostasis and permanent foreign body presence.

Inventive Principle:
Principle #40Composite materials

2Duration of action of stationary object

If absorbable materials are used for bone hemostasis, then osteogenesis is promoted, but hemostatic effectiveness is reduced

Engineering Contradiction:
Improveabsorption timeVSAvoidhemostatic effect
Core Design Contradiction:
Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent optimizes the degradation rate parameters of absorbable polymers to ensure they maintain structural integrity and hemostatic function during the critical initial period, then gradually absorb. This parameter optimization allows absorbable materials to achieve both effective hemostasis and promoted osteogenesis.

Inventive Principle:
Principle #35Parameter changes

3Speed

If electrocautery is used for hemostasis, then rapid bleeding control is achieved, but tissue damage occurs and osteogenesis is delayed

Engineering Contradiction:
Improvehemostasis speedVSAvoidtissue damage
Core Design Contradiction:
SpeedVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the thermal/electrical energy-based electrocautery method with a mechanically applicable absorbable putty material that achieves hemostasis through physical placement and gradual absorption. This substitution eliminates thermal tissue damage while maintaining effective bleeding control.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

4Duration of action of stationary object

If paste-like materials are used to fill bone defects, then osteogenesis is induced, but adherence to injured bone is poor and hemostasis is ineffective

Engineering Contradiction:
Improveabsorption timeVSAvoidadherence and hemostasis
Core Design Contradiction:
Duration of action of stationary objectVSReliability

Solution Approach 1:

The invention creates composite putty materials combining absorbable polymer matrices with particulate bone graft materials or other osteoinductive agents. This composite structure provides both effective adherence to bone surfaces and induced osteogenesis, while maintaining hemostatic capability.

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The patent creates materials with spatially varying properties - the outer surface provides adherence and hemostasis, while the internal structure promotes osteogenesis and controlled absorption. This local quality differentiation resolves the contradiction between adherence effectiveness and osteoinductive capability.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions offer rapid absorption, improved bone healing, reduced infection risk, and enhanced visibility during surgical procedures, addressing the limitations of existing materials by providing effective mechanical hemostasis and osteoinductive properties.

Implementation Method 1

absorbable formulations

Methodology Applied
Scientific EffectHydrolysis: Hydrolysis

Implementation Method 2

rapid absorption

Methodology Applied
Scientific EffectBiodegradation: Decomposition (biological)

Data Source

PatentUS8105628B2Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
Publication Date: 2012.01.31 ABYRX INC

AI summary

Two (or more), -component, body-implantable, absorbable, biocompatible, putty, and non-putty hemostatic tamponades for use in surgery. Component 1 is a finely powdered bulking material, preferably less than 50 microns, e.g. the calcium, magnesium, aluminum, or barium salts of saturated or unsaturated carboxylic acids containing about 6 to 22 carbon atoms, hydroxyapatite, DBM, polyglycolide, polylactide, polydioxinones, polycaprolactones, absorbable glasses, gelatin, collagens, mono, and polysaccharides starches. Component 2, a dispersing vehicle, may be esters of C8-C18 monohydric alcohols with C2-C6 aliphatic monocarboxylic acids; C2-C18 monohydric alcohols with polycarboxylic acids; C8-C30 monohydric alcohols; tocopherol and esters thereof with C2-C10 aliphatic monocarboxylic acids or polycarboxylic acids; absorbable 10-14C hydrocarbons; free carboxylic acids such as oleic, capric, and lauric; dialkyl ethers and ketones; alkyl aryl ethers and ketones, polyhydroxy compounds and esters and ethers thereof; (ethylene oxide/propylene oxide copolymers), oils e.g. olive oil, castor oil and triglycerides.